EA202092700A1 - COMPOSITIONS CONTAINING VEGETABLE RECEPTOR PROTEIN IN HIGH CONCENTRATION - Google Patents

COMPOSITIONS CONTAINING VEGETABLE RECEPTOR PROTEIN IN HIGH CONCENTRATION

Info

Publication number
EA202092700A1
EA202092700A1 EA202092700A EA202092700A EA202092700A1 EA 202092700 A1 EA202092700 A1 EA 202092700A1 EA 202092700 A EA202092700 A EA 202092700A EA 202092700 A EA202092700 A EA 202092700A EA 202092700 A1 EA202092700 A1 EA 202092700A1
Authority
EA
Eurasian Patent Office
Prior art keywords
high concentration
compositions containing
receptor protein
containing vegetable
formulations
Prior art date
Application number
EA202092700A
Other languages
Russian (ru)
Inventor
Кеннет С. Грэхем
Саурабх Вадхва
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Priority claimed from PCT/US2019/031879 external-priority patent/WO2019217927A1/en
Publication of EA202092700A1 publication Critical patent/EA202092700A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к офтальмологическим составам, имеющим высокие концентрации слитого белка рецептора фактора роста сосудистого эндотелия (ФРЭС) и высокую стабильность при хранении. Также предложены способы лечения ангиогенных заболеваний глаз с применением высококонцентрированных составов.This invention relates to ophthalmic formulations having high concentrations of vascular endothelial growth factor receptor (VEGF) fusion protein and high storage stability. Also proposed are methods for the treatment of angiogenic eye diseases using highly concentrated formulations.

EA202092700A 2019-03-05 2019-05-10 COMPOSITIONS CONTAINING VEGETABLE RECEPTOR PROTEIN IN HIGH CONCENTRATION EA202092700A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962813882P 2019-03-05 2019-03-05
PCT/US2019/031879 WO2019217927A1 (en) 2018-05-10 2019-05-10 High concentration vegf receptor fusion protein containing formulations

Publications (1)

Publication Number Publication Date
EA202092700A1 true EA202092700A1 (en) 2021-02-02

Family

ID=74855492

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092700A EA202092700A1 (en) 2019-03-05 2019-05-10 COMPOSITIONS CONTAINING VEGETABLE RECEPTOR PROTEIN IN HIGH CONCENTRATION

Country Status (1)

Country Link
EA (1) EA202092700A1 (en)

Similar Documents

Publication Publication Date Title
PH12020551839A1 (en) High concentration vegf receptor fusion protein containing formulations
PE20170900A1 (en) METHODS AND FORMULATIONS TO TREAT VASCULAR DISEASES OF THE EYES
CY1123657T1 (en) STABLE PHARMACEUTICAL FORM OF ANTI-IFNAR1
CY1114244T1 (en) VEGF COMPONENT COMPONENTS FOR SUITABLE INTERVENTAL ADMINISTRATION
MX2017016907A (en) A stable liquid formulation of fusion protein with igg fc domain.
AR089507A1 (en) IMMUNOGLOBULIN Fc VARIANTS
EA201591176A1 (en) COMPOSITIONS AND METHODS WITH THE USE OF PEPTIDE MARK, CONNECTED WITH HYALURONANE
PE20200695A1 (en) ANTIBODIES THAT RECOGNIZE TAU
PE20170142A1 (en) FUSION PROTEIN INHIBITING ANGIOGENESIS OR GROWTH AND USE OF THE SAME
AR102595A1 (en) ANTI-ANG2 ANTIBODIES AND METHODS OF USE
AR089787A1 (en) STABILIZED FORMULATIONS CONTAINING ANTI-ANG2 ANTIBODIES
EA200700380A1 (en) CONJUGATES OF GLYCEROLICOLORBED POLYETHYLENE GLYCOL - HUMAN GROWTH HORMONE, METHOD OF THEIR PRODUCTION AND METHODS OF THEIR APPLICATION
PE20140982A1 (en) LINKS THAT JOIN THE TRANSFORMANT GROWTH FACTOR-BETA RECEPTOR II
EA201992570A1 (en) COMPOSITIONS BASED ON HUMAN ANTIBODIES TO RANKL, AND ALSO WAYS OF THEIR APPLICATION
CL2021003081A1 (en) Modified membrane-like serine protease 1 (mtsp-1) polypeptides and methods of use (divisional of application no. 201903813)
EP3278810A4 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
EA201790889A1 (en) OPHALMOLOGICAL SOLUTION
EA201892493A1 (en) Neurotoxin liquid formulation stabilized by tryptophane or tyrosine
MX363822B (en) Liposome formulations.
EA202190744A1 (en) GLP1-FC FUSION PROTEIN AND ITS CONJUGATE
EA202090947A1 (en) COMPOSITIONS AND METHODS FOR CD5 + CELL DEPLETION
EA202092767A1 (en) HETEROCONDENSED PYRIDON COMPOUNDS AND THEIR USE AS IDH INHIBITORS
AR079683A1 (en) OPTICAL TOPIC FORMULATION OF PEPTIDES
CL2004001996A1 (en) ANTI-VEGF APTAMEROS (VASCULAR ENDOTELIAL GROWTH FACTOR) WITH 5'-5 'OR 3'-3' INVERTED NUCLEOTIDIC BLOCK, COMPOSITION CONTAINING IT, USEFUL FOR NEOVASCULARIZATION DISORDERS.
EA202192925A1 (en) SOLID FORMS OF THE GLYT1 INHIBITOR